Literature DB >> 22418633

Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention.

Sara E Cosgrove1, Susan K Seo, Maureen K Bolon, Kent A Sepkowitz, Michael W Climo, Daniel J Diekema, Kathleen Speck, Vidhya Gunaseelan, Gary A Noskin, Loreen A Herwaldt, Edward Wong, Trish M Perl.   

Abstract

OBJECTIVE: To evaluate the impact of postprescription review of broad-spectrum antimicrobial (study-ABX) agents on rates of antimicrobial use.
DESIGN: Quasi-experimental before-after study.
SETTING: Five academic medical centers. PATIENTS: Adults receiving at least 48 hours of study-ABX.
METHODS: The baseline, intervention, and follow-up periods were 6 months each in 2 units at each of 5 sites. Adults receiving at least 48 hours of study-ABX entered the cohort as case-patients. During the intervention, infectious-diseases physicians reviewed the cases after 48 hours of study-ABX. The provider was contacted with alternative recommendations if antimicrobial use was considered to be unjustified on the basis of predetermined criteria. Acceptance rates were assessed 48 hours later. The primary outcome measure was days of study-ABX per 1,000 study-patient-days in the baseline and intervention periods.
RESULTS: There were 1,265 patients in the baseline period and 1,163 patients in the intervention period. Study-ABX use decreased significantly during the intervention period at 2 sites: from 574.4 to 533.8 study-ABX days/1,000 patient-days (incidence rate ratio [IRR], 0.93; 95% confidence interval [CI], 0.88-0.97; P = .002) at hospital B and from 615.6 to 514.4 study-ABX days/1,000 patient-days (IRR, 0.83; 95% CI, 0.79-0.88; P < .001) at hospital D. Both had established antimicrobial stewardship programs (ASP). Study-ABX use increased at 2 sites and stayed the same at 1 site. At all institutions combined, 390 of 1,429 (27.3%) study-ABX courses were assessed as unjustified; recommendations to modify or stop therapy were accepted for 260 (66.7%) of these courses.
CONCLUSIONS: Postprescription review of study-ABX decreased antimicrobial utilization in some of the study hospitals and may be more effective when performed as part of an established ASP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418633     DOI: 10.1086/664771

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  23 in total

1.  Antimicrobial stewardship as part of the infection prevention effort.

Authors:  Rebekah W Moehring; Deverick J Anderson
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

2.  What Is the More Effective Antibiotic Stewardship Intervention: Preprescription Authorization or Postprescription Review With Feedback?

Authors:  Pranita D Tamma; Edina Avdic; John F Keenan; Yuan Zhao; Gobind Anand; James Cooper; Rebecca Dezube; Steven Hsu; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2017-03-01       Impact factor: 9.079

3.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

4.  "Choosing Wisely Canada" and antimicrobial stewardship: A shared focus on reducing unnecessary care.

Authors:  K B Born; J A Leis; W L Gold; W Levinson
Journal:  Can Commun Dis Rep       Date:  2015-06-18

5.  Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship.

Authors:  Jimish M Mehta; Kevin Haynes; E Paul Wileyto; Jeffrey S Gerber; Daniel R Timko; Steven C Morgan; Shawn Binkley; Neil O Fishman; Ebbing Lautenbach; Theoklis Zaoutis
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-23       Impact factor: 3.254

6.  Factors Influencing Antibiotic-Prescribing Decisions Among Inpatient Physicians: A Qualitative Investigation.

Authors:  Daniel Livorsi; Amber Comer; Marianne S Matthias; Eli N Perencevich; Matthew J Bair
Journal:  Infect Control Hosp Epidemiol       Date:  2015-06-16       Impact factor: 3.254

7.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

8.  Association of Adverse Events With Antibiotic Use in Hospitalized Patients.

Authors:  Pranita D Tamma; Edina Avdic; David X Li; Kathryn Dzintars; Sara E Cosgrove
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

9.  Current State of Antimicrobial Stewardship at Solid Organ and Hematopoietic Cell Transplant Centers in the United States.

Authors:  Susan K Seo; Kaming Lo; Lilian M Abbo
Journal:  Infect Control Hosp Epidemiol       Date:  2016-07-26       Impact factor: 3.254

10.  Decreasing ICU-associated Clostridioides difficile infection through fluoroquinolone restriction, the FIRST trial: a study protocol.

Authors:  Nasia Safdar; Vishala Parmasad; Roger Brown; Pascale Carayon; Alexander Lepak; John C O'Horo; Lucas Schulz
Journal:  BMJ Open       Date:  2021-06-29       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.